What is the recommended apixaban regimen, including dose, duration, and dose adjustments, for the acute treatment of pulmonary embolism?

Apixaban Regimen for Acute Pulmonary Embolism

For acute pulmonary embolism treatment, administer apixaban 10 mg orally twice daily for the first 7 days, followed by 5 mg twice daily for at least 3 months, with no initial parenteral anticoagulation required. 1, 2

Initial Treatment Phase (First 7 Days)

• Dose: Apixaban 10 mg orally twice daily 1, 2
• No lead-in heparin required: Unlike dabigatran and edoxaban, apixaban does not require initial parenteral anticoagulation 1
• Timing: Can be initiated immediately upon diagnosis without waiting for heparin bridging 2

Continuation Phase (Day 8 through Month 3-6)

• Dose: Apixaban 5 mg orally twice daily 1, 2
• Minimum duration: Continue for at least 3 months 1
• Efficacy: This regimen demonstrated non-inferiority to enoxaparin/warfarin with superior safety (major bleeding 0.6% vs 1.8%, P<0.001) in the AMPLIFY trial 1

Dose Adjustments for Renal Impairment

• Severe renal impairment (CrCl <15 mL/min): Apixaban is contraindicated 1, 2
• Moderate renal impairment (CrCl 15-29 mL/min): Use with caution; patients with CrCl <25 mL/min were excluded from clinical trials 1
• No dose adjustment needed: For CrCl ≥30 mL/min during acute treatment phase 2

Extended Treatment Phase (After 6 Months)

For patients requiring extended anticoagulation beyond 6 months, reduce to apixaban 2.5 mg orally twice daily. 1

• Indication: Unprovoked PE or persistent risk factors requiring indefinite anticoagulation 1
• Reduced-dose efficacy: Apixaban 2.5 mg twice daily demonstrated effectiveness in preventing recurrent VTE with lower bleeding risk compared to full-dose therapy 1, 3
• Reassessment: Evaluate bleeding risk, drug tolerance, and renal/hepatic function at regular intervals 1

Duration of Treatment Algorithm

Provoked PE (major transient risk factor): Discontinue after 3 months 1

Unprovoked PE or persistent risk factors: Continue indefinitely with reduced-dose (2.5 mg twice daily) after initial 6 months 1, 4

Recurrent VTE: Indefinite anticoagulation required 1

Minor transient risk factor with enduring risk factors: Extended therapy with reduced-dose apixaban (2.5 mg twice daily) reduces recurrent VTE risk (1.3% vs 10.0% with placebo, P<0.001) 4

Special Populations

Cancer-Associated PE

• Initial treatment: Same dosing as non-cancer patients (10 mg twice daily for 7 days, then 5 mg twice daily) 5
• Efficacy: Apixaban demonstrated non-inferiority to dalteparin (recurrent VTE 5.6% vs 7.9%) without increased bleeding (3.8% vs 4.0%) in the Caravaggio trial 5
• Extended treatment in cancer: Reduced-dose apixaban (2.5 mg twice daily) after 6 months is non-inferior to full-dose with less bleeding (12.1% vs 15.6%, P=0.03) 3
• Note: LMWH remains preferred by some guidelines due to limited cancer patient enrollment in initial trials (2.7% in AMPLIFY) 1

Contraindications

• Severe renal impairment (CrCl <15 mL/min): Absolute contraindication 1, 2
• Antiphospholipid antibody syndrome: Do not use; vitamin K antagonists are required 1
• Severe hepatic impairment: Avoid in patients with transaminases >2× upper limit of normal or bilirubin >1.5× upper limit of normal 1
• Pregnancy and lactation: Contraindicated 1

Missed Dose Management

• If dose missed: Take as soon as remembered on the same day, then resume twice-daily schedule 2
• Do not double dose: Never take two doses simultaneously to compensate for missed dose 2

Perioperative Management

• Moderate/high bleeding risk procedures: Discontinue at least 48 hours prior 2
• Low bleeding risk procedures: Discontinue at least 24 hours prior 2
• Restart timing: Resume when adequate hemostasis established 2
• Bridging: Generally not required during the 24-48 hour interruption 2

Common Pitfalls to Avoid

• Do not use initial heparin: Unlike dabigatran/edoxaban, apixaban does not require lead-in parenteral anticoagulation 1
• Do not reduce dose during acute phase: The 10 mg twice daily for 7 days is critical; do not use 2.5 mg dose initially 2
• Do not use atrial fibrillation dosing: PE requires different dosing than atrial fibrillation (which uses 5 mg or 2.5 mg twice daily throughout) 2
• Do not forget the 7-day loading phase: Starting directly at 5 mg twice daily is inadequate for acute PE 1, 2